Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California... Show more
Skye Bioscience, Inc. is a San Diego-based, clinical-stage biotechnology company that develops molecules modulating G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and related metabolic diseases. Its lead clinical asset, nimacimab, is a peripherally restricted, negative allosteric modulating antibody targeting the cannabinoid receptor 1 (CB1), designed to avoid the central nervous system side effects that historically limited small-molecule CB1 inhibitors. The company is pre-revenue, has no approved products, and has historically funded operations primarily through equity issuances.
Investors followed SKYE for its differentiated, non-incretin approach to the large and competitive obesity market. Nimacimab was evaluated as both a monotherapy and in combination with GLP-1 therapies such as semaglutide, positioning Skye against major players including Novo Nordisk and Eli Lilly.
Over the last 30 days, SKYE declined approximately 29%, moving from a close near $1.57 in mid-October to roughly $1.11. The decline was not linear; selling pressure intensified in early November as the stock slid from about $0.99 to an intraday low near $0.51 before stabilizing. Trading volume spiked well above its historical average during the move, reflecting elevated uncertainty among holders.
The quarterly picture is even more pronounced. Three months ago, the stock traded near $4.33; at roughly $1.11, SKYE has lost about 74% over the period. The sharpest leg lower coincided with the August announcement of a strategic transaction, after which the shares re-rated substantially lower as the market digested the company's shift away from its legacy obesity program.
The recent 30-day decline was driven primarily by funding and strategic uncertainty rather than a single earnings surprise. Management has stated that available capital is expected to fund operations only through the fourth quarter of 2026, excluding the cost of any future Phase 2b study. With no product revenue and continued development spending, investors have reassessed the company's near-term financing risk.
Selling accelerated into the company's expected quarterly results and funding update, as holders awaited clarity on how Skye would finance its operations following the pause of nimacimab development. Additional pressures included reported insider selling by an institutional holder, the September resignation of Chief Financial Officer John Sharp, and downgrades from several analysts following the obesity trial readout. These developments compounded the negative sentiment already embedded in the stock.
The broader three-month decline traces to a fundamental shift in the company's strategy. In the second quarter of 2026, Skye made a capital allocation decision to discontinue its CBeyond Phase 2a trial and pause development of nimacimab, engaging a financial advisor to evaluate strategic alternatives. While nimacimab had demonstrated additional weight loss in combination with semaglutide, management cited a rapidly evolving anti-obesity landscape and the substantial investment required to remain competitive.
In August, Skye announced an agreement to acquire Redx Pharma through a scheme of arrangement, forming Fibrx Therapeutics, a Nasdaq-listed, fibrosis-focused company backed by $125 million in financing and led by the pan-ROCK inhibitor RXC008 for fibrostenotic Crohn's disease. Under the terms, pre-transaction Skye shareholders retain a minority stake and contingent value rights tied to any future monetization of nimacimab. The transaction effectively repositioned SKYE's value proposition, prompting a sustained de-rating as investors reassessed what the shares would represent going forward.
Tickeron's Trending AI Robots page highlights a curated selection of the platform's top-performing automated trading systems. While Tickeron hosts hundreds of AI-powered trading bots that monitor thousands of tickers across various markets, only the most relevant and highest-performing bots are surfaced in this section. These bots differ in strategy, holding timeframe, and performance metrics, allowing users to compare approaches suited to their own objectives. For investors tracking volatile, event-driven names in the biotechnology sector, the page offers a way to observe how algorithmic strategies respond to fast-changing conditions. Exploring the section can provide additional perspective on automated trading approaches.
Looking ahead, the key variables for SKYE include the completion and terms of the Redx Pharma transaction and the formation of Fibrx Therapeutics, as well as the outcome of the contingent value rights tied to any monetization of nimacimab. Shareholder approvals and proxy-related votes represent additional milestones. Investors should also monitor the company's cash position and any financing announcements, given the runway guidance into late 2026.
On the clinical front, progress of RXC008 in fibrostenotic Crohn's disease and the broader fibrosis pipeline will be central to the combined entity's outlook. Competitive dynamics in both obesity and fibrosis, regulatory decisions, and analyst revisions are additional factors likely to influence sentiment. As with any early-stage, pre-revenue biotechnology company, these drivers carry meaningful risk and uncertainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
SKYE saw its Momentum Indicator move below the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned negative. In 82 of the 90 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SKYE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for SKYE entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for SKYE's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 60 of 69 cases where SKYE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for SKYE just turned positive on November 12, 2026. Looking at past instances where SKYE's MACD turned positive, the stock continued to rise in 35 of 39 cases over the following month. The odds of a continued upward trend are 90%.
Following a +18.61% 3-day Advance, the price is estimated to grow further. Considering data from situations where SKYE advanced for three days, in 197 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
SKYE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.817) is normal, around the industry mean (3.596). P/E Ratio (-0.097) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.130) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. SKYE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKYE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology